R5XA Stock Overview
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Talphera, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.86 |
| 52 Week High | US$1.33 |
| 52 Week Low | US$0.39 |
| Beta | 0.48 |
| 1 Month Change | -17.05% |
| 3 Month Change | -13.54% |
| 1 Year Change | 39.64% |
| 3 Year Change | -96.06% |
| 5 Year Change | -98.75% |
| Change since IPO | -98.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| R5XA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -9.7% | 2.5% | 1.8% |
| 1Y | 39.6% | -27.7% | 2.2% |
Return vs Market: R5XA exceeded the German Market which returned -0.3% over the past year.
Price Volatility
| R5XA volatility | |
|---|---|
| R5XA Average Weekly Movement | 14.8% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Volatility Over Time: R5XA's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 15 | Vince Angotti | talphera.com |
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.
Talphera, Inc. Fundamentals Summary
| R5XA fundamental statistics | |
|---|---|
| Market cap | €15.02m |
| Earnings (TTM) | -€9.62m |
| Revenue (TTM) | €609.08k |
24.7x
P/S Ratio-1.6x
P/E RatioIs R5XA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| R5XA income statement (TTM) | |
|---|---|
| Revenue | US$651.00k |
| Cost of Revenue | US$498.00k |
| Gross Profit | US$153.00k |
| Other Expenses | US$10.44m |
| Earnings | -US$10.29m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.61 |
| Gross Margin | 23.50% |
| Net Profit Margin | -1,580.18% |
| Debt/Equity Ratio | 0% |
How did R5XA perform over the long term?
See historical performance and comparison